Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

114P - Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial


23 Nov 2019


Poster display session


Tumour Site

Colon and Rectal Cancer


Jun Zhu


Annals of Oncology (2019) 30 (suppl_9): ix30-ix41. 10.1093/annonc/mdz421


J.L. Zhu1, S. Li1, C. Zhu2

Author affiliations

  • 1 Department Of Oncology, Jiangsu Province Cancer Hospital, 210009 - Nanjing/CN
  • 2 Department Of Oncology, The First Affiliated Hospital of Soochow University, 215000 - Suzhou/CN


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 114P


There are limited treatment options after failure of first-line fluoropyrimidine-based chemotherapy in mCRC. We studied the efficacy and safety of bevacizumab plus raltitrexed-based (Saiweijian®) chemotherapy as second-line therapy in Chinese patients with mCRC.


Trial design: Open-label, single-arm, multicenter, phase II trial (NCT03126071).100 patients were required. Enrolled patients were treated with BEV+SALIRI(bevacizumab 7.5mg/kg d1, raltitrexed 3mg/m2 d1, irinotecan 250mg/m2 d1,q3w) or BEV+SALOX(bevacizumab 7.5mg/kg d1,raltitrexed 3mg/m2 d1, oxaliplatin 130mg/m2 d1,q3w)(depending on first-line regimen). Patients treated for 6 cycles with efficacy evaluation SD or above were followed by maintenance therapy(bevacizumab7.5 mg/kg d1, raltitrexed 3 mg/m2 d1,q3w) until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), overall survival (OS), quality of life (QOL) and safety.


Between 12/2016 and 5/2019, 63 patients were enrolled. [The median age was 58 years(range:27-74 years), ECOG PS 1 scored 95.2%. ] A total of 376 cycles were completed and 21 patients recieved maintenance therapy. 56 patients were evaluable and ORR was 26.8%, DCR was 78.6%. 52 patients reached the primary endpoint,the median PFS (mPFS) was 5.7 months (95% CI: 1.5-16.7), the median OS (mOS) was not observed. Adverse events (AE) were mostly grade 1/2, and ≧grade 3 treatment-related AEs were mainly neutropenia (7.9%), leukopenia (6.3%), thrombocytopenia (6.3%), alanine aminotransferase increased (4.8%), aspartate aminotransferase increased (6.3%), nausea (3.2%), diarrhea (4.8%) and fatigue (3.2%).


Our interim results suggest that the combination of bevacizumab with raltitrexed-based chemotherapy could be an efficient and safe second-line treatment option for patients with mCRC. This trial will progress as planned.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.